NEW DRUGS

Cytalux, a Novel Imaging Agent, FDA Approved for Diagnosing Inoperable Ovarian Cancer Lesions

JHOP - December 2021 Vol 11, No 6 - FDA Oncology Update
Download PDF

On November 29, 2021, the FDA accelerated the approval of pafolacianine (Cytalux; On Target Laboratories), a novel fluorescent imaging agent, for adults with ovarian cancer as an adjunct for identifying inoperable malignant lesions. Pafolacianine targets the folate receptor, which may be overexpressed in ovarian cancer. It is used with a near-infrared fluorescence imaging system approved specifically for use with pafolacianine. Pafolacianine received orphan drug designation for this indication.

The FDA approved pafolacianine based on a single-arm, multicenter, open-label study of 178 women with ovarian cancer or with high clinical suspicion of ovarian cancer who were scheduled to have surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery.

All the patients received pafolacianine. In addition to standard-of-care evaluation, 134 received fluorescence imaging evaluation; of these, 36 (26.9%) patients had at least 1 evaluable ovarian cancer lesion detected with pafolacianine that was not detected by standard evaluation. The false-positive rate with pafolacianine in detecting ovarian cancer lesions confirmed by central pathology was 20.2% (95% confidence interval, 13.7%-28.0%).

The most common (≥1%) adverse events were nausea, vomiting, abdominal pain, flushing, dyspepsia, chest discomfort, pruritus, and hypersensitivity.

The recommended pafolacianine dose is 0.025 mg/kg, administered intravenously over 60 minutes, 1 to 9 hours before surgery.

Related Items
FDA-Approved Nirogacestat Demonstrates Improved Patient Outcomes in Desmoid Tumor Management
Web Exclusives published on February 12, 2024 in FDA Oncology Update
Iwilfin FDA Approved for Adults and Pediatric Patients with High-Risk Neuroblastoma
Web Exclusives published on January 17, 2024 in FDA Oncology Update
Welireg Now FDA Approved for Patients with Advanced Renal Cell Carcinoma
Web Exclusives published on January 17, 2024 in FDA Oncology Update
Keytruda Plus Chemotherapy Receives New FDA Approvals for Advanced Biliary Tract Cancer and 2 Forms of Advanced Gastroesophageal Junction Adenocarcinoma
Web Exclusives published on December 19, 2023 in FDA Oncology Update
FDA Approved Loqtorzi, a PD-1 Inhibitor, for the Treatment of Adults With Metastatic or Recurrent Nasopharyngeal Carcinoma
Web Exclusives published on December 18, 2023 in FDA Oncology Update
Tibsovo FDA Approved for Patients With Relapsed Myelodysplastic Syndromes and IDH1 Mutation
Web Exclusives published on December 18, 2023 in FDA Oncology Update
Fruzaqla FDA Approved for Refractory Metastatic Colorectal Cancer
JHOP - December 2023 Vol 13, No 6 published on December 6, 2023 in FDA Oncology Update
Rozlytrek Now Approved for Pediatric Patients Older Than 1 Month With Solid Tumors and NTRK Gene Fusion and in New Oral Pellet Form
JHOP - December 2023 Vol 13, No 6 published on December 6, 2023 in FDA Oncology Update
FDA Authorizes Updated COVID-19 Vaccine Formulations for Better Protection Against Current Variants
JHOP - December 2023 Vol 13, No 6 published on November 17, 2023 in FDA Oncology Update
Bosulif Now FDA Approved for Pediatric Patients With Chronic Myelogenous Leukemia
JHOP - December 2023 Vol 13, No 6 published on November 3, 2023 in FDA Oncology Update
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: